Institut de Recherche pour le Développement (IRD), Université Montpellier 1, UMR 145, Montpellier, F-34000, France.
BMC Infect Dis. 2010 Jun 19;10:179. doi: 10.1186/1471-2334-10-179.
Although a dramatic decrease in AIDS progression has been observed after Highly Active Anti Retroviral Therapy (HAART) in both low- and high-resource settings, few data support that fact in low-resource settings.This study describes the incidence of AIDS-defining illnesses (ADI) after HAART initiation and analyzes their risk factors in a low-resource setting. A focus was put on CD4 cell counts and viral load measurements.
404 HIV-1-infected Senegalese adult patients were enrolled in a prospective observational cohort and data censored as of April 2008. A Poisson regression was used to model the incidence of ADIs over two periods and to assess its association with baseline variables, current CD4, current viral load, CD4 response, and virological response.
ADI incidence declined from 20.5 ADIs per 100 person-years, 95% CI = [16.3;25.8] during the first year to 4.3, 95% CI = [2.3;8.1] during the fourth year but increased afterwards. Before 42 months, the decrease was greater in patients with clinical stage CDC-C at baseline and with a viral load remaining below 1000 cp/mL but was uniform across CD4 strata (p = 0.1). After 42 months, 293 patients were still at risk. The current CD4 and viral load were associated with ADI incidence (decrease of 21% per 50 CD4/mm3 and of 61% for patients with a viral load < 1000 cp/mL).
During the first four years, a uniform decline of ADI incidence was observed even in patients with low CD4-cell counts at HAART initiation as long as the viral load remained undetectable. An increase was noted later in patients with immunologic and virological failures but also in patients with only virological failure.
尽管在低资源和高资源环境下,高效抗逆转录病毒治疗(HAART)后艾滋病的进展都明显减少,但在低资源环境下,仅有少数数据支持这一事实。本研究描述了低资源环境下 HAART 启动后艾滋病定义性疾病(ADI)的发生率,并分析了其危险因素。研究重点放在 CD4 细胞计数和病毒载量的测量上。
404 名感染 HIV-1 的塞内加尔成年患者被纳入前瞻性观察队列,数据截止至 2008 年 4 月。采用泊松回归模型来模拟两个时期内 ADI 的发生率,并评估其与基线变量、当前 CD4、当前病毒载量、CD4 反应和病毒学反应的相关性。
ADI 的发生率从第一年的 20.5 例/100 人年(95%CI=[16.3;25.8])下降到第四年的 4.3 例/100 人年(95%CI=[2.3;8.1]),但随后又有所上升。在 42 个月之前,基线时临床分期为 CDC-C 和病毒载量持续低于 1000 cp/mL 的患者下降幅度更大,但在 CD4 分层中分布均匀(p = 0.1)。在 42 个月之后,仍有 293 名患者处于危险之中。当前的 CD4 和病毒载量与 ADI 的发生率相关(每增加 50 CD4/mm3,ADI 的发生率下降 21%;病毒载量<1000 cp/mL 的患者,ADI 的发生率下降 61%)。
在最初的四年中,只要病毒载量仍无法检测到,即使在 HAART 启动时 CD4 细胞计数较低的患者中,也观察到 ADI 发生率的均匀下降。在免疫和病毒学失败的患者中,以及仅在病毒学失败的患者中,后来都出现了发生率的增加。